Exercise of warrants

RNS Number : 6997W

Oxford Biomedica PLC

18 April 2019

 

Exercise of warrants

London, UK - 18 April 2019: Oxford Biomedica plc ("Oxford Biomedica", "the Company" or "the Group") (LSE:OXB), a leading gene and cell therapy group, announces that it has received notification from Oaktree Capital Management ("Oaktree") to exercise warrants representing 2,689,686 ordinary shares of 50p each ("Ordinary Shares") in the Company for total consideration of £1,344,843. The exercise price of the warrants was 50p per warrant.

Applications have been made for the Ordinary Shares to be admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (together, "Admission"). Admission is expected to take place at 8.00 a.m. on 26 April 2019.

Total voting rights

Following Admission, the Company's issued share capital will consist of 68,860,324 ordinary shares of 50p each. The new Ordinary Shares will rank pari passu with the existing ordinary shares. There are no ordinary shares held in treasury. Accordingly, the total number of voting rights in Oxford Biomedica plc at Admission will be 68,860,324.

The above figure 68,860,324 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Stuart Paynter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com

 

END

 

 

IOEUWONRKRASAAR